Sorsby's fundus dystrophy (SFD) is a rare autosomal dominant macular disorder with age of onset usually in the fourth decade. It is characterised by loss of central vision owing to subretinal neovascularisation and disciform macular degeneration. In an effort to identify the SFD gene, the disease locus was first mapped to chromosome 22ql3-qter by genetic linkage analysis, the same chromosomal region as the gene encoding the tissue inhibitor of metalloproteinases-3 (TIMP3). Subsequently, two separate mutations in TIMP3 were found in affected members of two unrelated SFD pedigrees (Tyrl68Cys and Serl8lCys). More recently, two additional SFD related mutations, Serl56Cys and Glyl67Cys, have provided further confirmation that heterozygous mutations in TIMP3 are causally responsible for the SFD phenotype. We now report the occurrence of the Tyr168Cys mutation in an SFD patient ofAustrian descent and show that this mutation found earlier in an American SFD family arose independently. The new findings add to an emerging pattern of SFD mutations which all seem to affect the C-terminal region of the mature TIMP3 protein. In addition, all known mutations cause a change of an amino acid to a cysteine residue. This suggests a critical role for the additional C-terminal free thiol group in SFD pathogenesis. (J3Med Genet 1996;33:233-236) Key words: Sorsby's fundus dystrophy; mutational analysis; tissue inhibitor of metalloproteinases-3 (TIMP3).
SFD gene, the disease locus was first mapped to chromosome 22ql3-qter by genetic linkage analysis, the same chromosomal region as the gene encoding the tissue inhibitor of metalloproteinases-3 (TIMP3). Subsequently, two separate mutations in TIMP3 were found in affected members of two unrelated SFD pedigrees (Tyrl68Cys and Serl8lCys). More recently, two additional SFD related mutations, Serl56Cys and Glyl67Cys, have provided further confirmation that heterozygous mutations in TIMP3 are causally responsible for the SFD phenotype. We now report the occurrence of the Tyr168Cys mutation in an SFD patient ofAustrian descent and show that this mutation found earlier in an American SFD family arose independently. The new findings add to an emerging pattern of SFD mutations which all seem to affect the C-terminal region of the mature TIMP3 protein. In addition, all known mutations cause a change of an amino acid to a cysteine residue. This suggests a critical role for the additional C-terminal free thiol group in SFD pathogenesis. The macular dystrophies represent a large group of distinct disorders that affect central vision. In this group, age related macular degeneration (AMD) has an estimated prevalence of almost 20% in the population over 65 years of age in developed countries.' To facilitate the development of adequate therapeutic treatment, it is important to gain insights into the basic pathogenesis of these macular disorders. Clinical similarities in the early disease processes of some forms of macular degeneration have often been noted and are of particular interest for the understanding of the genetically complex AMD. Based on some common histopathological features, particularly at the level 85  ex IR  TCG GGC GGG GCA CCA GGA  109  2  ex 2  TCG TGT TCC TGA TGT GGT T  AluI  90  ex 2R   CGG AGC CAG GGT GAT GAC  81  3  ex 3  GGA AAG AAG AAG CTA TGA TG  Hinfl  96  ex 3R  AGA AAC AGT GGA CCT TGG C  106  4  ex4  GACAAAACAACCTCTCCT T  RsaI  65  ex4R  TCAGCACCTCCCCTCCTT  139  5  2FF  GTC CAT To increase sensitivity of the single stranded conformational polymorphism (SSCP) analysis,'3 the PCR products were digested with various restriction enzymes to yield fragments <200 bp (table) . A combination of two gel running conditions was applied using 6% non-denaturing polyacrylamide gels with (5%) and without glycerol at 4°C, 25 W constant power for four to seven hours.
Exon 5 PCR fragments were cloned into the pCR II vector (Invitrogen). Recombinant clones were sequenced using the dideoxy nucleotide chain termination method (USB, Cleveland) and sequencing primers M13(-40)F (5'-GTT TTC CCA GTC ACG A-3') and M13 (-40)R (5'-CAG GAA ACA GCT ATG AC-3'). Genotyping was performed using (CA)n dinucleotide repeat markers at loci D22S275 and D22S281 and PCR conditions as described. 14 The intragenic polymorphism in exon 3 ofthe TIMP3 gene is the result ofa silent mutation in codon 60 and 64, respectively, and can be analysed by SSCP of exon 3 PCR fragments amplified with primers ex3/ex3R (table) .
Results
To test the Austrian patient for mutations in TIMP3, we performed SSCP of the entire coding sequence of the gene. Analysis of exon 5 showed a band shift ( fig 1A) which was not found in her two brothers or in 270 unaffected controls. However, this mobility shift was similar to a TIMP3 mutation in exon 5 previously identified in an American SFD family.9 Sequencing of the mutant allele showed an A to G transition in the second position of codon 168 changing a highly conserved tyrosine residue7 1516 to a cysteine ( fig 1B) . These alterations are identical to the findings in the American SFD family.9
To ascertain whether the Tyrl68Cys mutation in the American SFD family9 and our Austrian SFD patient originated from a common ancestor, we genotyped the critical subjects with (CA)L dinucleotide repeat markers at D22S275 and D22S281 as well as a frequent intragenic SSCP in exon 3 of the TIMP3 gene. The Austrian patient does not carry the particular alleles at D22S275 and D22S281 associated with SFD in the American family ( fig  2A) . In addition, the intragenic SSCP in exon 3 shows that the band shift segregating with SFD in the American family is not shared by the Austrian SFD patient ( fig 2B) .
Discussion
To date, four different mutations have been identified in TIMP3 in patients diagnosed with Sorsby's fundus dystrophy, including a Ser156Cys mutation in a German-Czech family with an atypical early onset and a rapid progression of the disease,'0 a Glyl 67Cys mutation,'1 a Tyri 68Cys mutation in an American family,9 and a Sern81Cys mutation in a Canadian family of Irish descent.9 In addition, we report here a second Tyrl68Cys mutation in an Austrian patient and unambiguously show its independent occurrence from the identical American mutation.
Despite this relatively small number of known mutations in SFD, a mutational pattern underlying the disease appears to emerge. So far, all mutations have been identified in exon 5 of the TIMP3 gene, thus affecting the Cterminal region ofthe mature protein. Although little is known about the kinetics of TIMP3 action, the C-terminal domains of TIMPI and TIMP2 are thought to increase binding stability between the inhibitor and its matrix metalloproteinases and, thus, to influence the rate of inhibition through low affinity interactions.'718 In addition, the N-terminal domains of TIMP1 and TIMP2 alone retain metalloproteinase inhibitory function and appear not to require their C-terminal domains for full activity. '9 20 This suggests that the mutational changes in the C-terminal domain of TIMP3 may not fully interfere with TIMP3 inhibitory function and could explain, at least in part, the late onset of symptoms usually in the fourth decade of life.3 Similarly, partial activity of the mutated TIMP3 protein could also account for the absence of pathological features in other body tissues with high TIMP3 expression. 715 It is striking that all known TIMP3 mutations lead to the introduction of an additional cysteine residue in the peptide sequence suggesting that the mechanism underlying the SFD pathology may be directly related to the presence of a free thiol group in the C-terminal part of the peptide. This raises the question of whether other types of mutations in the TIMP3 gene could be responsible for other as yet unknown clinical conditions different from SFD. The study of transgenic animals carrying various types of mutations in the TIMP3 gene may provide some clues to the effect of specific mutations on the resulting clinical phenotype.
